[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @plainyogurt21 Adu Subramanian Adu Subramanian posts on X about mcp, mbx, market cap, $mbx the most. They currently have XXXXX followers and XX posts still getting attention that total XXXXX engagements in the last XX hours. ### Engagements: XXXXX [#](/creator/twitter::791473106007097345/interactions)  - X Week XXXXXX -XX% - X Month XXXXXXX +242% - X Months XXXXXXX +3.30% - X Year XXXXXXX +625% ### Mentions: XX [#](/creator/twitter::791473106007097345/posts_active)  - X Week XX +36% - X Month XX +181% - X Months XXX +113% - X Year XXX +238% ### Followers: XXXXX [#](/creator/twitter::791473106007097345/followers)  - X Week XXXXX +0.89% - X Month XXXXX +3.90% - X Months XXXXX +19% - X Year XXXXX +51% ### CreatorRank: XXXXXXX [#](/creator/twitter::791473106007097345/influencer_rank)  ### Social Influence [#](/creator/twitter::791473106007097345/influence) --- **Social category influence** [stocks](/list/stocks) XXXX% [finance](/list/finance) XXXX% [technology brands](/list/technology-brands) XXXX% [cryptocurrencies](/list/cryptocurrencies) XXXX% [currencies](/list/currencies) XXXX% [countries](/list/countries) XXXX% **Social topic influence** [mcp](/topic/mcp) 5.88%, [mbx](/topic/mbx) 3.92%, [market cap](/topic/market-cap) 3.92%, [$mbx](/topic/$mbx) 3.92%, [insurance](/topic/insurance) 3.92%, [$qure](/topic/$qure) #1, [$jspr](/topic/$jspr) 3.92%, [$alny](/topic/$alny) 1.96%, [$bbio](/topic/$bbio) 1.96%, [pfe](/topic/pfe) XXXX% **Top accounts mentioned or mentioned by** [@barry3252181](/creator/undefined) [@a_may_md](/creator/undefined) [@masonat7](/creator/undefined) [@houndcl](/creator/undefined) [@melvinriskmgmt](/creator/undefined) [@ejliv850](/creator/undefined) [@desertdweller93](/creator/undefined) [@amaymd](/creator/undefined) [@erikotto2](/creator/undefined) [@17thfellow](/creator/undefined) [@theswissfrank](/creator/undefined) [@3rdfloorcapital](/creator/undefined) [@joserestonva](/creator/undefined) [@dragonmaxgoku](/creator/undefined) [@biotenic](/creator/undefined) [@dmitrykovalchuk](/creator/undefined) [@west0cap](/creator/undefined) [@sanctuarybio](/creator/undefined) [@applehelix](/creator/undefined) [@stockblues](/creator/undefined) **Top assets mentioned** [Marblex (MBX)](/topic/$mbx) [Alnylam Pharmaceuticals, Inc. (ALNY)](/topic/$alny) [BridgeBio Pharma, Inc. Common Stock (BBIO)](/topic/$bbio) [Pfizer, Inc. (PFE)](/topic/$pfe) [Bitcoin Incognito (XBI)](/topic/$xbi) [Cere Network (CERE)](/topic/$cere) [Reata Pharmaceuticals, Inc. Class A Common Stock (RETA)](/topic/$reta) [Eli Lilly and Company (LLY)](/topic/$lly) [AstraZeneca PLC (AZN)](/topic/$azn) [United Therapeutics, Corp. (UTHR)](/topic/$uthr) [Celldex Therapeutics, Inc (CLDX)](/topic/$cldx) ### Top Social Posts [#](/creator/twitter::791473106007097345/posts) --- Top posts by engagements in the last XX hours "Not using it officially why I specified its to see the future I think its best used for a deep research use case so Im waiting for chatGPT to come out with something. I will also likely create a better MCP for clin trials when they do Want and will likely do/brqnch MCP for clin trials FDA (labels and docs) pubmed semantic scholar investor presentations anything else for an investor/biotech"  [@plainyogurt21](/creator/x/plainyogurt21) on [X](/post/tweet/1946008501228068988) 2025-07-18 00:45:56 UTC 4092 followers, XXX engagements "Let's do some basic counting: how many patients with a "response" are still on treatment I count 3:"  [@plainyogurt21](/creator/x/plainyogurt21) on [X](/post/tweet/1940466386192793988) 2025-07-02 17:43:33 UTC 4084 followers, 3293 engagements "$ALNY $BBIO and there we have it. Commercial policy from united healthcare requires prior ATTRUBY or VYNDA for using vutrisiran. Not a universal step edit but on the margins this cuts out a significant % of the population"  [@plainyogurt21](/creator/x/plainyogurt21) on [X](/post/tweet/1941881988920512625) 2025-07-06 15:28:39 UTC 4092 followers, 42K engagements "@17thfellow $PFE will buy them replace tafa revenue"  [@plainyogurt21](/creator/x/plainyogurt21) on [X](/post/tweet/1945943720898990526) 2025-07-17 20:28:31 UTC 4089 followers, XXX engagements "$MBX Back on this And I think it's worth a shot. ASND has launched strong in HypoPTH and $SEPN failed. A weekly injectable would be helpful as a pseudo "basal- bolus" regimen (we've actually seen this work in HypoPTH using insulin pumps instead of twice daily admin). Keep in mind ASND moved up XX% when $SEPN failed in February that's a few B in market cap. Phase X trial has issues with vitamin D urinary calcium fluctuations in bone deposition but they can be explained. HERE IS THE BOTTOM LINE IMO If we can get PTH levels to normal levels then the drug should work in patients with HypoPTH. MBX"  [@plainyogurt21](/creator/x/plainyogurt21) on [X](/post/tweet/1939739312897024511) 2025-06-30 17:34:25 UTC 4083 followers, 3230 engagements "Maybe people are finally looking at $ELDN R &D day"  [@plainyogurt21](/creator/x/plainyogurt21) on [X](/post/tweet/1944790133867167875) 2025-07-14 16:04:35 UTC 4092 followers, 2232 engagements "$stim interesting is this a way to play spravato launch and psychedelics as a proxy"  [@plainyogurt21](/creator/x/plainyogurt21) on [X](/post/tweet/1945084963797283139) 2025-07-15 11:36:07 UTC 4086 followers, 1252 engagements "Time to jinx it $XBI $VRNA $PROK $NKTR $CDTX to name a few"  [@plainyogurt21](/creator/x/plainyogurt21) on [X](/post/tweet/1942993359406027094) 2025-07-09 17:04:50 UTC 4092 followers, 1646 engagements "$STOK Some math on the Biogen Deal and I think it works out to about 800M in peak ROW sales 700M market cap 380M cash. assumes XX% PoS from Biogen side"  [@plainyogurt21](/creator/x/plainyogurt21) on [X](/post/tweet/1944079476834349076) 2025-07-12 17:00:41 UTC 4092 followers, 4478 engagements "Yea drugs are goated but you ever own a stock predict a readout and it hits exactly. That's a real fucking drug"  [@plainyogurt21](/creator/x/plainyogurt21) on [X](/post/tweet/1943262508661235837) 2025-07-10 10:54:20 UTC 4084 followers, XXX engagements "@Sanctuary_Bio @AppleHelix @stockblues @A_May_MD @Sports_bios @AndyBiotech How many people have made theses on the back of X paid Y for this company $RETA $CERE $GBT (Im guilty of this one)"  [@plainyogurt21](/creator/x/plainyogurt21) on [X](/post/tweet/1941950346600866248) 2025-07-06 20:00:16 UTC 4089 followers, XXX engagements "Its an interesting question: how much credit do they get with XX% of the weight loss but all fat mass Less total fat lost but better body composition (frankly Id prefer that over a GLP1). An alternative to building muscle via myostatin is. A six month injection. But issue with that is proving benefit to insurance companies in addition to weight loss. Already have GLP1 trouble unless uncontrolled diabetes"  [@plainyogurt21](/creator/x/plainyogurt21) on [X](/post/tweet/1945990078838325295) 2025-07-17 23:32:44 UTC 4091 followers, XXX engagements "I don't think this expands the market: if you have the gene you will have the disease. but it will pull forward demand away from long term competition IF QURE shows a strong benefit (5 years slowing). I would be cautious about the eligible patient range and FDA label for it. If it's not on label (becuase not in the trial) then no way insurance covers it"  [@plainyogurt21](/creator/x/plainyogurt21) on [X](/post/tweet/1945941710074532079) 2025-07-17 20:20:32 UTC 4089 followers, XXX engagements "@JoseRestonVA Any good MCP use cases youve found The current ones arent there quite yet but getting better quickly"  [@plainyogurt21](/creator/x/plainyogurt21) on [X](/post/tweet/1946156549564502293) 2025-07-18 10:34:13 UTC 4091 followers, XXX engagements "$NAMS Underrated commercial bull thesis vs lp(a) and PCSK9 is type of doc for the patient. CETP can be used by PCP comfortable with orals and the billin while any injectable is handoff to the cardiology Further if they do reduce alzheimer's risk it's an easy sell"  [@plainyogurt21](/creator/x/plainyogurt21) on [X](/post/tweet/1945936875136409986) 2025-07-17 20:01:19 UTC 4092 followers, 2112 engagements "@AB1001_disciple @DesertDweller93 When would alnylam be set for approval"  [@plainyogurt21](/creator/x/plainyogurt21) on [X](/post/tweet/1945855802364879155) 2025-07-17 14:39:10 UTC 4092 followers, XXX engagements "We already have a tough time selling the test for Lp(a) and that won't change. PCPs know how to see elevated LDL levels and manage that. See this UptoDate Guideline. no mention of Lp(a) ANy commercial bear argument is moot imo. YOu have to believe Prevail fails to be bearish"  [@plainyogurt21](/creator/x/plainyogurt21) on [X](/post/tweet/1945937885166764528) 2025-07-17 20:05:20 UTC 4092 followers, 1038 engagements "@houndcl @avidresearch @jfais20 Approval in mono - use in maintenance"  [@plainyogurt21](/creator/x/plainyogurt21) on [X](/post/tweet/1945974783591547221) 2025-07-17 22:31:57 UTC 4088 followers, XXX engagements "while we start ascribing too. much value to anecdotes here's a patient in $QURE Study: "I regret being part of the study.""  [@plainyogurt21](/creator/x/plainyogurt21) on [X](/post/tweet/1946276999980331268) 2025-07-18 18:32:51 UTC 4092 followers, 5032 engagements "$JSPR. What do you do on a readout that you need to raise cash to fund your blockbuster Mess up manufacturing"  [@plainyogurt21](/creator/x/plainyogurt21) on [X](/post/tweet/1942239969545798042) 2025-07-07 15:11:08 UTC 4084 followers, 2543 engagements "$TECX $LLY $AZN. I think Volenrelaxin failed for two reasons. 1) wrong population. Acute decompensating HFpEF patients are not Group X PH. We had mixed evidence for relaxin in HF now we know it doesn't work. The renal selective vasodilation doesn't improve the mortality output enough 2) LARS as an endpoint is no bueno. I think this one is harder to grok. LARS is an echo endpoint a proxy for left atrial filling. Catheterization measures this a little more directly. Reducing volume overload should reduce LARS. but it's just a proxy. It's sown mixed results and the endpoint is noisy in HFpEF."  [@plainyogurt21](/creator/x/plainyogurt21) on [X](/post/tweet/1944581648852365817) 2025-07-14 02:16:08 UTC 4092 followers, 4710 engagements "$LQDA $UTHR Interesting quirk here: Teton X is all US Teton X all ROW. TETON X reads out this year first. The ROW study started a year later and recruited faster. Could be an interesting scenario where Teton X is negative but TETON X is positive. Fibroneer Phase X study showed much higher (double the benefit) in asian patients. But TETON X only enrolls patient South america EU Taiwan. Wonder how much the SoC is different across geographies. Enrollment speed could be an indicator of excitement. EDIT: I think UTHR has ODD for X years in IPF. so not a catalyst for $LQDA. T/y to @bigpharmaguy"  [@plainyogurt21](/creator/x/plainyogurt21) on [X](/post/tweet/1941115291913609384) 2025-07-04 12:42:04 UTC 4092 followers, 3580 engagements "So $CLDX what;s the bear case and why didn't the $JSPR debacle benefit them"  [@plainyogurt21](/creator/x/plainyogurt21) on [X](/post/tweet/1943123324613136876) 2025-07-10 01:41:16 UTC 4089 followers, 1913 engagements "if you have claude try out installing this MCP server Not perfect but I want everyone to try it and see the future in real time. No more navigating the clin trials stuff imo. Gonna be asking Claude to do it for me"  [@plainyogurt21](/creator/x/plainyogurt21) on [X](/post/tweet/1945929822556852383) 2025-07-17 19:33:17 UTC 4092 followers, 2938 engagements "Why isn't $CTNM JNJ5120 on the JNJ development pipeline website data 2H25"  [@plainyogurt21](/creator/x/plainyogurt21) on [X](/post/tweet/1943288937721512106) 2025-07-10 12:39:21 UTC 4092 followers, 1261 engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@plainyogurt21 Adu Subramanian
Adu Subramanian posts on X about mcp, mbx, market cap, $mbx the most. They currently have XXXXX followers and XX posts still getting attention that total XXXXX engagements in the last XX hours.
Engagements: XXXXX #
- X Week XXXXXX -XX%
- X Month XXXXXXX +242%
- X Months XXXXXXX +3.30%
- X Year XXXXXXX +625%
Mentions: XX #
- X Week XX +36%
- X Month XX +181%
- X Months XXX +113%
- X Year XXX +238%
Followers: XXXXX #
- X Week XXXXX +0.89%
- X Month XXXXX +3.90%
- X Months XXXXX +19%
- X Year XXXXX +51%
CreatorRank: XXXXXXX #
Social Influence #
Social category influence stocks XXXX% finance XXXX% technology brands XXXX% cryptocurrencies XXXX% currencies XXXX% countries XXXX%
Social topic influence mcp 5.88%, mbx 3.92%, market cap 3.92%, $mbx 3.92%, insurance 3.92%, $qure #1, $jspr 3.92%, $alny 1.96%, $bbio 1.96%, pfe XXXX%
Top accounts mentioned or mentioned by @barry3252181 @a_may_md @masonat7 @houndcl @melvinriskmgmt @ejliv850 @desertdweller93 @amaymd @erikotto2 @17thfellow @theswissfrank @3rdfloorcapital @joserestonva @dragonmaxgoku @biotenic @dmitrykovalchuk @west0cap @sanctuarybio @applehelix @stockblues
Top assets mentioned Marblex (MBX) Alnylam Pharmaceuticals, Inc. (ALNY) BridgeBio Pharma, Inc. Common Stock (BBIO) Pfizer, Inc. (PFE) Bitcoin Incognito (XBI) Cere Network (CERE) Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) Eli Lilly and Company (LLY) AstraZeneca PLC (AZN) United Therapeutics, Corp. (UTHR) Celldex Therapeutics, Inc (CLDX)
Top Social Posts #
Top posts by engagements in the last XX hours
"Not using it officially why I specified its to see the future I think its best used for a deep research use case so Im waiting for chatGPT to come out with something. I will also likely create a better MCP for clin trials when they do Want and will likely do/brqnch MCP for clin trials FDA (labels and docs) pubmed semantic scholar investor presentations anything else for an investor/biotech"
@plainyogurt21 on X 2025-07-18 00:45:56 UTC 4092 followers, XXX engagements
"Let's do some basic counting: how many patients with a "response" are still on treatment I count 3:" @plainyogurt21 on X 2025-07-02 17:43:33 UTC 4084 followers, 3293 engagements
"$ALNY $BBIO and there we have it. Commercial policy from united healthcare requires prior ATTRUBY or VYNDA for using vutrisiran. Not a universal step edit but on the margins this cuts out a significant % of the population" @plainyogurt21 on X 2025-07-06 15:28:39 UTC 4092 followers, 42K engagements
"@17thfellow $PFE will buy them replace tafa revenue" @plainyogurt21 on X 2025-07-17 20:28:31 UTC 4089 followers, XXX engagements
"$MBX Back on this And I think it's worth a shot. ASND has launched strong in HypoPTH and $SEPN failed. A weekly injectable would be helpful as a pseudo "basal- bolus" regimen (we've actually seen this work in HypoPTH using insulin pumps instead of twice daily admin). Keep in mind ASND moved up XX% when $SEPN failed in February that's a few B in market cap. Phase X trial has issues with vitamin D urinary calcium fluctuations in bone deposition but they can be explained. HERE IS THE BOTTOM LINE IMO If we can get PTH levels to normal levels then the drug should work in patients with HypoPTH. MBX" @plainyogurt21 on X 2025-06-30 17:34:25 UTC 4083 followers, 3230 engagements
"Maybe people are finally looking at $ELDN R &D day" @plainyogurt21 on X 2025-07-14 16:04:35 UTC 4092 followers, 2232 engagements
"$stim interesting is this a way to play spravato launch and psychedelics as a proxy" @plainyogurt21 on X 2025-07-15 11:36:07 UTC 4086 followers, 1252 engagements
"Time to jinx it $XBI $VRNA $PROK $NKTR $CDTX to name a few" @plainyogurt21 on X 2025-07-09 17:04:50 UTC 4092 followers, 1646 engagements
"$STOK Some math on the Biogen Deal and I think it works out to about 800M in peak ROW sales 700M market cap 380M cash. assumes XX% PoS from Biogen side" @plainyogurt21 on X 2025-07-12 17:00:41 UTC 4092 followers, 4478 engagements
"Yea drugs are goated but you ever own a stock predict a readout and it hits exactly. That's a real fucking drug" @plainyogurt21 on X 2025-07-10 10:54:20 UTC 4084 followers, XXX engagements
"@Sanctuary_Bio @AppleHelix @stockblues @A_May_MD @Sports_bios @AndyBiotech How many people have made theses on the back of X paid Y for this company $RETA $CERE $GBT (Im guilty of this one)" @plainyogurt21 on X 2025-07-06 20:00:16 UTC 4089 followers, XXX engagements
"Its an interesting question: how much credit do they get with XX% of the weight loss but all fat mass Less total fat lost but better body composition (frankly Id prefer that over a GLP1). An alternative to building muscle via myostatin is. A six month injection. But issue with that is proving benefit to insurance companies in addition to weight loss. Already have GLP1 trouble unless uncontrolled diabetes" @plainyogurt21 on X 2025-07-17 23:32:44 UTC 4091 followers, XXX engagements
"I don't think this expands the market: if you have the gene you will have the disease. but it will pull forward demand away from long term competition IF QURE shows a strong benefit (5 years slowing). I would be cautious about the eligible patient range and FDA label for it. If it's not on label (becuase not in the trial) then no way insurance covers it" @plainyogurt21 on X 2025-07-17 20:20:32 UTC 4089 followers, XXX engagements
"@JoseRestonVA Any good MCP use cases youve found The current ones arent there quite yet but getting better quickly" @plainyogurt21 on X 2025-07-18 10:34:13 UTC 4091 followers, XXX engagements
"$NAMS Underrated commercial bull thesis vs lp(a) and PCSK9 is type of doc for the patient. CETP can be used by PCP comfortable with orals and the billin while any injectable is handoff to the cardiology Further if they do reduce alzheimer's risk it's an easy sell" @plainyogurt21 on X 2025-07-17 20:01:19 UTC 4092 followers, 2112 engagements
"@AB1001_disciple @DesertDweller93 When would alnylam be set for approval" @plainyogurt21 on X 2025-07-17 14:39:10 UTC 4092 followers, XXX engagements
"We already have a tough time selling the test for Lp(a) and that won't change. PCPs know how to see elevated LDL levels and manage that. See this UptoDate Guideline. no mention of Lp(a) ANy commercial bear argument is moot imo. YOu have to believe Prevail fails to be bearish" @plainyogurt21 on X 2025-07-17 20:05:20 UTC 4092 followers, 1038 engagements
"@houndcl @avidresearch @jfais20 Approval in mono - use in maintenance" @plainyogurt21 on X 2025-07-17 22:31:57 UTC 4088 followers, XXX engagements
"while we start ascribing too. much value to anecdotes here's a patient in $QURE Study: "I regret being part of the study."" @plainyogurt21 on X 2025-07-18 18:32:51 UTC 4092 followers, 5032 engagements
"$JSPR. What do you do on a readout that you need to raise cash to fund your blockbuster Mess up manufacturing" @plainyogurt21 on X 2025-07-07 15:11:08 UTC 4084 followers, 2543 engagements
"$TECX $LLY $AZN. I think Volenrelaxin failed for two reasons. 1) wrong population. Acute decompensating HFpEF patients are not Group X PH. We had mixed evidence for relaxin in HF now we know it doesn't work. The renal selective vasodilation doesn't improve the mortality output enough 2) LARS as an endpoint is no bueno. I think this one is harder to grok. LARS is an echo endpoint a proxy for left atrial filling. Catheterization measures this a little more directly. Reducing volume overload should reduce LARS. but it's just a proxy. It's sown mixed results and the endpoint is noisy in HFpEF." @plainyogurt21 on X 2025-07-14 02:16:08 UTC 4092 followers, 4710 engagements
"$LQDA $UTHR Interesting quirk here: Teton X is all US Teton X all ROW. TETON X reads out this year first. The ROW study started a year later and recruited faster. Could be an interesting scenario where Teton X is negative but TETON X is positive. Fibroneer Phase X study showed much higher (double the benefit) in asian patients. But TETON X only enrolls patient South america EU Taiwan. Wonder how much the SoC is different across geographies. Enrollment speed could be an indicator of excitement. EDIT: I think UTHR has ODD for X years in IPF. so not a catalyst for $LQDA. T/y to @bigpharmaguy" @plainyogurt21 on X 2025-07-04 12:42:04 UTC 4092 followers, 3580 engagements
"So $CLDX what;s the bear case and why didn't the $JSPR debacle benefit them" @plainyogurt21 on X 2025-07-10 01:41:16 UTC 4089 followers, 1913 engagements
"if you have claude try out installing this MCP server Not perfect but I want everyone to try it and see the future in real time. No more navigating the clin trials stuff imo. Gonna be asking Claude to do it for me" @plainyogurt21 on X 2025-07-17 19:33:17 UTC 4092 followers, 2938 engagements
"Why isn't $CTNM JNJ5120 on the JNJ development pipeline website data 2H25" @plainyogurt21 on X 2025-07-10 12:39:21 UTC 4092 followers, 1261 engagements